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offset in four of the six studies (median, -$21; range -$35 to 
-$0.50). In one case, the GI event offsets (due to the unusually
high cost of treating minor GI) were greater than the additional
cost of the coxib. CONCLUSIONS: Variation in drug acquisi-
tion cost of NSAIDs relative to coxibs was more important in
contributing to the variation in results but the variations in clin-
ical inputs and in costs of GI events were also important. More
investigation into the reasons for differences in costs and clini-
cal input is needed.
MC2
EVALUATION OF MEDICATION ADHERENCE IN CHRONIC
OBSTRUCTIVE PULMONARY DISEASE
Kim JW1, Livengood KB2, Nichol MB1
1University of Southern California, School of Pharmacy, Los Angeles,
CA, USA; 2Pﬁzer Inc, New York, NY, USA
OBJECTIVES: Although there has been research published on
the topic of medication adherence in chronic obstructive pul-
monary disease (COPD), nothing in the literature describes the
association between patient-reported adherence and clinical out-
comes. This study examines the relationship between two
patient-reported adherence measures and clinical outcomes in
COPD. METHODS: Three-hundred and twenty COPD patients
from seven geographically diverse sites across the United States
were enrolled from April 2003 to November 2003 and admin-
istered both the Morisky Medication Adherence Scale (MMAS)
and Inhaler Adherence Scale (IAS) questionnaires. Subsequently,
retrospective chart review was conducted to collect demo-
graphic, laboratory, and clinical data for each participant. The
association between patient-reported medication adherence and
FEV1 and FEV1 % predicted was determined using both ordi-
nary least squares (OLS) regression and a parametric two-step
sample selection model. RESULTS: Both the MMAS and IAS
indicated the majority of participants appear to be adherent with
their medication regimen. The results derived from the two-step
sample selection model demonstrated that every one-point
increase in IAS score was associated with an increase in both
FEV1 (p = 0.0003) and FEV1 % predicted (p = 0.0008). Pro-
gression of disease was signiﬁcantly associated with a decrease
in both FEV1 (p = 0.004) and FEV1 % predicted (p = 0.041).
Medication adherence, as measured by the MMAS, was not asso-
ciated with a signiﬁcant change in either FEV1 or FEV1 % pre-
dicted. CONCLUSIONS: The IAS appears to be a tool that
clearly demonstrates the association between patient-reported
medication adherence and signiﬁcantly improved clinical out-
comes in COPD. The IAS also appears to be superior to the
MMAS in this respect.
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OBJECTIVE: To examine if method of case ascertainment affects
estimates of the prevalence and severity of dementia in Medicare
nursing home residents. METHODS: A nationally-representative
sample of Medicare beneﬁciaries residing in skilled-nursing facil-
ities (N = 1100) was identiﬁed from the Medicare Current Ben-
eﬁciary Survey (MCBS) for 2001. The MCBS contains detailed
information from medical records and personal interviews on
socio-demographics, health and medical conditions, and health
care use. Survey information can be linked to Medicare claims,
drug administration records, and Minimum Data Set (MDS).
Dementia prevalence rates were determined using following four
sources of diagnosis information, alone and in combinations:
survey, MDS, Medicare claims, and drugs for dementia treat-
ment. Concordance between sources for dementia diagnosis was
measured as percent agreement and with kappa statistics. The
severity of dementia cases from each source was determined
using cognitive, physical, and behavioral functioning limitation
measures from MDS. Chi-square tests were performed to iden-
tify statistically signiﬁcant differences at p < 0.05. RESULTS:
Among four measures considered singly, the lowest dementia
rates were obtained using drugs (12.4%) and the highest using
claims (57.3%). Rates were higher when sources were combined
and reached 68% using all four sources together. As for con-
cordance, the percent agreement ranged from a low of 19.2%
between claims and drugs to a high of 97.5% between drugs and
claims with survey or MDS. Kappa statistics were the lowest
between drugs and survey or MDS with claims (kappa 0.12), and
were highest between survey and MDS (kappa 0.70). Sources
were similar in the severity of dementia cases. CONCLUSIONS:
Although there was a wide variation in prevalence and concor-
dance of dementia cases by diagnostic source, there was no sys-
tematic bias based on disease severity. A combination of all 
four sources presents the most inclusive measure of disease
prevalence available to researchers working on dementia in 
long-term care.
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OBJECTIVES: The purpose of this study was to illustrate how
decision-making could be affected by the choice of preference-
based algorithms for the SF-36 and SF-12, and provide some
guidance on selecting an appropriate algorithm. METHODS:
Two sets of data were used: 1) a clinical trial of adult asthma
patients; and 2) a longitudinal study of post-stroke patients.
Incremental costs were assumed to be $2000 per year over stan-
dard treatment, and QALY gains realized over a 1-year period.
Ten published algorithms were identiﬁed, denoted by ﬁrst
author: Brazier (SF-36), Brazier (SF-12), Shmueli, Fryback,
Lundberg, Nichol, Franks (3 algorithms), and Lawrence. Incre-
mental cost-utility ratios (ICURs) for each algorithm, stated in
dollars per quality-adjusted life year ($/QALY), were ranked and
compared between datasets. RESULTS: In the asthma pati-
ents, ICURs ranged from Lawrence’s SF-12 algorithm at
$30,769/QALY to Brazier’s SF-36 algorithm at $63,492/QALY.
ICURs for the stroke cohort varied slightly more dramatically.
The MEPS-based algorithm by Franks et al. provided the lowest
ICUR at $27,972/QALY. The Fryback and Shmueli algorithms
provided ICURs that were greater than $50,000/QALY. The
ICUR-based ranking of algorithms was strongly correlated
between the asthma and stroke datasets (r = 0.69). CONCLU-
SIONS: SF-36/SF-12 preference-based algorithms produced a
wide range of ICURs that could potentially lead to different
reimbursement decisions. Brazier’s SF-36 and SF-12 algorithms
have a strong methodological and theoretical basis and tended
to generate relatively higher ICUR estimates, considerations that
support a preference for this algorithm over the alternatives. The
“second-generation” algorithms developed from preferences
mapped from other indirect preference-based measures tended to
generate lower ICURs that would promote greater adoption of
new technology. There remains a need for an SF-36/SF-12 pref-
erence-based algorithm based on the US general population that
has strong theoretical and methodological foundations.
